Captrust Financial Advisors Invests $343,000 in Penumbra, Inc. (NYSE:PEN)

Captrust Financial Advisors bought a new position in Penumbra, Inc. (NYSE:PEN - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 1,445 shares of the company's stock, valued at approximately $343,000.

Other large investors have also modified their holdings of the company. Baillie Gifford & Co. lifted its stake in shares of Penumbra by 23.4% in the fourth quarter. Baillie Gifford & Co. now owns 730,233 shares of the company's stock worth $173,416,000 after buying an additional 138,387 shares during the last quarter. T. Rowe Price Investment Management Inc. lifted its position in Penumbra by 47.4% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 707,061 shares of the company's stock worth $167,913,000 after purchasing an additional 227,506 shares during the period. Bank of America Corp DE raised its position in Penumbra by 19.9% in the fourth quarter. Bank of America Corp DE now owns 346,528 shares of the company's stock worth $82,293,000 after purchasing an additional 57,421 shares in the last quarter. Dimensional Fund Advisors LP grew its position in Penumbra by 23.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 323,964 shares of the company's stock valued at $76,937,000 after acquiring an additional 60,764 shares during the period. Finally, Northern Trust Corp lifted its holdings in Penumbra by 20.8% during the 4th quarter. Northern Trust Corp now owns 318,230 shares of the company's stock valued at $75,573,000 after purchasing an additional 54,890 shares during the last quarter. 88.88% of the stock is owned by institutional investors.

Penumbra Trading Down 0.2%

NYSE PEN opened at $281.04 on Wednesday. Penumbra, Inc. has a 12 month low of $148.00 and a 12 month high of $310.00. The company has a current ratio of 6.01, a quick ratio of 3.25 and a debt-to-equity ratio of 0.02. The stock's fifty day moving average price is $280.06 and its 200-day moving average price is $264.41. The stock has a market cap of $10.88 billion, a P/E ratio of 826.59, a P/E/G ratio of 2.83 and a beta of 0.53.

Penumbra (NYSE:PEN - Get Free Report) last announced its quarterly earnings data on Wednesday, April 23rd. The company reported $0.83 EPS for the quarter, beating the consensus estimate of $0.66 by $0.17. Penumbra had a net margin of 1.17% and a return on equity of 9.74%. The company had revenue of $324.14 million for the quarter, compared to the consensus estimate of $315.72 million. During the same period in the prior year, the firm posted $0.41 EPS. Penumbra's revenue for the quarter was up 16.3% on a year-over-year basis. As a group, equities analysts forecast that Penumbra, Inc. will post 3.67 EPS for the current fiscal year.

Insider Buying and Selling

In other Penumbra news, EVP Johanna Roberts sold 600 shares of the stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $287.43, for a total value of $172,458.00. Following the transaction, the executive vice president now owns 66,539 shares of the company's stock, valued at approximately $19,125,304.77. This represents a 0.89% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Lambert Shiu sold 501 shares of the firm's stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $282.88, for a total transaction of $141,722.88. Following the completion of the transaction, the chief accounting officer now directly owns 32,969 shares in the company, valued at approximately $9,326,270.72. The trade was a 1.50% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 176,696 shares of company stock worth $50,207,745 in the last three months. Insiders own 4.20% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the stock. Wells Fargo & Company upped their target price on shares of Penumbra from $305.00 to $315.00 and gave the stock an "overweight" rating in a research report on Thursday, April 24th. Piper Sandler reaffirmed an "overweight" rating and issued a $330.00 target price (up previously from $250.00) on shares of Penumbra in a research note on Wednesday, February 19th. Royal Bank of Canada increased their target price on Penumbra from $315.00 to $330.00 and gave the stock an "outperform" rating in a research note on Thursday, April 24th. BTIG Research restated a "buy" rating on shares of Penumbra in a report on Thursday, April 24th. Finally, Stifel Nicolaus set a $318.00 price objective on Penumbra and gave the stock a "buy" rating in a research note on Thursday, April 24th. Three research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, Penumbra currently has a consensus rating of "Moderate Buy" and an average target price of $302.40.

About Penumbra

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.